Conditions: Chronic Kidney Disease Type 2 Diabetes Mellitus
Keywords: albuminuria
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 154
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.

Detailed description:

Arms:
arm 1: AZD1722 in 5, 15, 30, or 60 mg capsules. Starting dose is 15 mg BID PO for 12 Weeks arm 2: Placebo capsule BID PO for 12 Weeks

Interventions: intervention 1: AZD1722 intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: Placebo for AZD1722

Protocol document: